Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Current Assets (2020 - 2023)

Candel Therapeutics' Current Assets history spans 4 years, with the latest figure at $45.1 million for Q3 2023.

  • For Q3 2023, Current Assets fell 42.96% year-over-year to $45.1 million; the TTM value through Sep 2023 reached $45.1 million, down 42.96%, while the annual FY2022 figure was $71.9 million, 15.3% down from the prior year.
  • Current Assets for Q3 2023 was $45.1 million at Candel Therapeutics, down from $53.4 million in the prior quarter.
  • Across five years, Current Assets topped out at $95.6 million in Q1 2022 and bottomed at $24.4 million in Q2 2021.
  • The 4-year median for Current Assets is $71.9 million (2022), against an average of $66.3 million.
  • The largest annual shift saw Current Assets surged 257.51% in 2022 before it tumbled 42.96% in 2023.
  • A 4-year view of Current Assets shows it stood at $35.1 million in 2020, then soared by 141.69% to $84.9 million in 2021, then decreased by 15.3% to $71.9 million in 2022, then crashed by 37.31% to $45.1 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Current Assets are $45.1 million (Q3 2023), $53.4 million (Q2 2023), and $61.9 million (Q1 2023).